Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
OS Therapies Incorporated ( (OSTX) ) just unveiled an announcement.
On October 17, 2025, OS Therapies Incorporated announced the posting of an investor presentation on their website, which they plan to use in discussions with investors and analysts. The company also held its annual meeting of stockholders on October 14, 2025, where key proposals were approved, but the meeting was adjourned to allow more time for proxy solicitation. The reconvened meeting is scheduled for October 21, 2025. This strategic move is part of OS Therapies’ efforts to engage stakeholders and ensure comprehensive participation in its decision-making processes.
The most recent analyst rating on (OSTX) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on OS Therapies Incorporated stock, see the OSTX Stock Forecast page.
Spark’s Take on OSTX Stock
According to Spark, TipRanks’ AI Analyst, OSTX is a Underperform.
OS Therapies Incorporated faces significant financial difficulties, marked by increasing net losses, negative cash flows, and reliance on external financing. The technical analysis indicates bearish momentum with the stock trading below its moving averages. Valuation is challenging with no earnings to support a P/E ratio or dividend yield. These factors contribute to a low overall stock score, reflecting the company’s financial instability and negative market sentiment.
To see Spark’s full report on OSTX stock, click here.
More about OS Therapies Incorporated
OS Therapies Incorporated operates in the biotechnology industry, focusing on the development of innovative cancer immunotherapy treatments. Their primary products include the OST-HER2 platform targeting osteosarcoma and other solid tumor cancers, and a next-generation tunable drug conjugate (tADC) platform. The company is positioned in the market with a focus on addressing unmet needs in cancer treatment, particularly in osteosarcoma, breast cancer, and other solid tumors.
Average Trading Volume: 498,050
Technical Sentiment Signal: Strong Sell
Current Market Cap: $62.04M
For an in-depth examination of OSTX stock, go to TipRanks’ Overview page.